Lenz Therapeutics Inc Revenue Growth Rates (LENZ), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lenz Therapeutics Inc   (NASDAQ: LENZ)
 

LENZ's Revenue Growth by Quarter and Year

Lenz Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LENZ Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 5.49
1st Quarter March 1.90
FY 7.39





LENZ Revenue second quarter 2026 Y/Y Growth Comment
Lenz Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue improvement of 9.72% year on year, to $ 5.49 millions.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue growth. While Lenz Therapeutics Inc ' s Revenue increase of 9.72% ranks overall at the positon no. 2383 in the second quarter 2026.


LENZ Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June 9.72 % - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Lenz Therapeutics Inc 's second quarter 2026 Revenue $ 5.49 millions LENZ's Income Statement
Lenz Therapeutics Inc 's second quarter 2025 Revenue $ 5.00 millions Quarterly LENZ's Income Statement


LENZ Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -87.28 % - -
3rd Quarter September - 150 % - -
2nd Quarter June 188.74 % - - -
1st Quarter March 19.5 % - - -
FY (Year on Year)   - - - -


Back to LENZ Growth rate Comparisons >> Back to LENZ Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #342
Overall #2383

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #342
Overall #2383
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Lenz Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
188.58 % 67.75 % -87.3 %
(Jun 30 2026)  


LENZ's II. Quarter Q/Q Revenue Comment
Lenz Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 188.74%, to $ 5.49 millions, from $1.90 millions in the first quarter.
LENZ is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Lenz Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 92.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #35
Overall #92
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #35
Overall #92
Revenue Q/Q Growth Statistics
High Average Low
188.58 % 67.75 % -87.3 %
(Jun 30 2026)  


LENZ's II. Quarter Q/Q Revenue Comment
Lenz Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 188.74%, to $ 5.49 millions, from $1.90 millions in the first quarter.
LENZ is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Lenz Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 92.


Lenz Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 21.48 $ 20.99 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 2.32 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 2383 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Lenz Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 9.72% year on year, to $ 21 millions if the fiscal year would have ended in Jun 30 2026.
Lenz Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Lenz Therapeutics Inc realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry.
But from twelve months ended Mar 31 2026 rise was beneth at 2.32 % from $20.99 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.

Lenz Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 342
S&P 500 # 2383
Cumulative Revenue growth Comment
Lenz Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 9.72% year on year, to $ 21 millions if the fiscal year would have ended in Jun 30 2026.
Lenz Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Lenz Therapeutics Inc realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry.
But from twelve months ended Mar 31 2026 rise was beneth at 2.32 % from $20.99 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 2.32 % increase from $20.99 millions in the period from Mar 31 2026 to Jun 30 2025.

Lenz Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 342
S&P 500 # 2383




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LENZ's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Cvrx inc 16.77%$ 16.766 millions
Regeneron Pharmaceuticals Inc 16.73%$ 16.735 millions
Invo Fertility Inc 16.73%$ 16.732 millions
Pro dex Inc 16.65%$ 16.646 millions
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions
Jazz Pharmaceuticals Plc15.55%$ 15.548 millions
Alphatec Holdings Inc 15.35%$ 15.349 millions
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions


About Lenz Therapeutics Inc Revenue Growth Rates (LENZ), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lenz Therapeutics Inc (CIK 1815776).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001815776-26-000052
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lenz Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.